From Model to Market: Enhancing Phase 3 Design with MID

16.01.2025, 10:15 - 11:45  –  2.9.2.22
SFB-Seminar

Jane Knöchel (AstraZeneca, Sweden)

Model Informed Drug Development (MIDD) has revolutionized the way pharmaceutical companies approach Phase 3 clinical trials. By integrating predictive modeling, MIDD enables more accurate and efficient trial designs, reducing costs and increasing the likelihood of success. This talk will explore how MIDD can be utilized to enhance Phase 3 clinical trial design, showcasing real-world examples of its application. Attendees will gain insights into the methodologies and strategies that leverage MIDD to predict outcomes, optimize sampling timepoints and dosing regimen, and streamline the regulatory approval process, ultimately accelerating the path from model to market.

 

zu den Veranstaltungen